From Basement Labs to GLP-1 Giant: The Novo Nordisk Century

The discovery of insulin in 1921 was a medical miracle, but turning that miracle into a reliable, global supply required something less celebrated: industrial persistence. Jennifer Mason's A History of Novo Nordisk tells how two separate Danish ventures — one born in a university lab, the other in a pharmacy basement — raced, then merged, to build a company that now shapes the treatment of diabetes, obesity, and rare bleeding disorders worldwide. The book is less a corporate hagiography than a case study in how scientific rigor, engineering pragmatism, and a distinctive Danish corporate ethos compounded across a century.

What the book is about

Mason structures the narrative across 25 chronological chapters, beginning with the Toronto insulin discovery and the parallel founding of Nordisk Insulinlaboratorium (Chapter 2) and Novo Terapeutisk Laboratorium (Chapter 3). The middle sections cover wartime survival (Chapter 5), the biotechnology pivot (Chapter 10), the 1989 merger (Chapter 7), and diversification into growth hormone and hemophilia (Chapter 14). Later chapters examine delivery-device innovation (Chapter 12), the GLP-1 revolution (Chapters 22–23), digital health integration (Chapter 21), and the company's evolving sustainability framework (Chapter 19). The work assumes no specialized scientific background but rewards readers familiar with pharmaceutical R&D, healthcare policy, or business history. Its primary audience includes industry professionals, medical historians, and general readers interested in how a single therapeutic class — insulin — seeded a global biopharma enterprise.

Two founding cultures, one shared mission

The book's early chapters draw a sharp contrast between Nordisk's academic pedigree and Novo's engineering grit. August Krogh, a Nobel laureate physiologist, and his physician wife Marie leveraged Krogh's Toronto connections to secure licensing rights and production know-how; Nordisk's early work unfolded in Krogh's University of Copenhagen laboratory. Meanwhile, brothers Harald (civil engineer) and Thorvald Pedersen (pharmacist) reverse-engineered insulin extraction in a Copenhagen pharmacy basement, backed by pharmacist August Kongsted. Mason notes that Nordisk's culture was "deeply scientific and humanitarian," while Novo's was defined by "practical ingenuity" and a "can-do attitude." This duality — research depth versus manufacturing agility — became a competitive engine: "The competitive dynamic, rather than being detrimental, proved to be a powerful catalyst for innovation and efficiency" (Chapter 3). The tension persisted until the 1989 merger, when leadership explicitly sought "the best of both worlds" (Chapter 15).

The merger as strategic necessity, not sentiment

Chapter 7 makes clear that the 1989 combination of Nordisk and Novo was driven by cold-eyed economics. Recombinant DNA technology had raised the R&D ante: "Developing these advanced therapies required significant investment, far beyond what either company could easily muster alone without considerable risk." Regulatory complexity was escalating, and global competitors were consolidating. The merged entity could pool intellectual property, harmonize manufacturing, and present a unified commercial front — especially critical for the transition from animal to human insulin. Mason describes the integration as "a monumental undertaking" that required "careful management to avoid disruption to ongoing operations, especially the continuous supply of life-saving insulin to patients worldwide." The new name, Novo Nordisk A/S, was "a deliberate combination, reflecting the equal partnership and the shared legacy." The merger chapter is a rare, detailed look at how two culturally distinct firms operationalize a consolidation without losing their innovative edge.

Biotechnology as a platform, not a product

The shift to recombinant human insulin in the 1980s (Chapter 10) was more than a process upgrade; it created a reusable technology platform. Once Novo Nordisk mastered expressing human proteins in microbial hosts, the same infrastructure — fermentation, purification, analytical characterization — could be redirected to growth hormone (Norditropin®) and Factor VIIa (NovoSeven®). Chapter 14 details how the Factor VIIa project "pushed Novo Nordisk's biotechnology capabilities to new frontiers, requiring mastery of mammalian cell culture and highly specialized purification techniques." This platform logic recurs in the GLP-1 programs: the peptide engineering expertise honed on insulin analogues enabled liraglutide and semaglutide. Mason argues that the company's "deep expertise in protein engineering and large-scale biomanufacturing became a significant competitive advantage" across therapeutic areas. The takeaway: sustainable biopharma leadership often depends on building modular scientific capabilities that outlive any single product.

Delivery devices as a durable moat

While competitors focused on molecule potency, Novo Nordisk invested heavily in the patient experience of injection. Chapter 12 traces a lineage from the 1925 Novo Syringe through the 1985 NovoPen® ("one of the world's first reusable insulin pens") to disposable pens like FlexPen® and FlexTouch®. Mason emphasizes that "the ease of use, coupled with the precision dosing features and the integration of finer needles, resonated deeply with patients" and "created a significant barrier to entry for competitors." The company positioned itself as "not just an insulin provider, but a comprehensive diabetes care partner." This device-centric strategy compounded: pen adoption facilitated intensive basal-bolus regimens, which in turn increased demand for rapid- and long-acting analogues. The symbiosis between drug and device is a recurring theme — and a reminder that in chronic disease, adherence economics can outweigh pure pharmacology.

From diabetes specialist to metabolic disease leader

The most dramatic strategic pivot occurs in Chapters 22 and 23. GLP-1 receptor agonists, initially developed for Type 2 diabetes, revealed potent weight-loss effects. Rather than treat this as a side effect, Novo Nordisk pursued higher-dose formulations specifically for obesity: Saxenda® (liraglutide 3.0 mg) and Wegovy® (semaglutide 2.4 mg). The STEP trial program demonstrated "average weight reductions of around 15–17% of initial body weight," a result "that rivaled bariatric surgery for some patients." Mason notes this required "building new commercial infrastructures and engaging with different medical specialties" and "advocating for a medicalized approach to obesity." The move reframed the company's identity: "Novo Nordisk's 21st-century R&D continued to explore other innovative targets… particularly focusing on areas of metabolic health beyond just glucose and weight." The obesity chapter illustrates how a firm can leverage an existing molecular platform to unlock an entirely new market — if it's willing to invest in new evidence, new messaging, and new access strategies.

Who should read this

Readers seeking a granular, well-sourced account of how a century-old insulin duopoly became a diversified biopharma leader will find this book rewarding. It is especially valuable for those in pharmaceutical strategy, healthcare investing, or medical innovation policy who want to see how R&D platform choices, manufacturing scale, device integration, and corporate culture interact over long time horizons. General business readers may find the chapter-by-chapter chronology dense; the book does not dramatize personalities or boardroom conflicts in the style of popular business narratives. But for anyone willing to follow the technical and operational detail, Mason delivers a clear-eyed map of how scientific breakthroughs become sustainable global enterprises — and how the next chapter (oral insulin, cell therapy, AI-driven discovery) is already being written.

Read “A History of Novo Nordisk” on MixCache.com →